Literature DB >> 27002519

Cancer Drugs Fund 2.0: A Missed Opportunity?

Christopher McCabe1, Ash Paul2, Greg Fell3, Mike Paulden4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27002519     DOI： 10.1007/s40273-016-0403-2

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  New 50 million pound cancer fund already intellectually bankrupt.

Authors: 
Journal:  Lancet       Date:  2010-08-07       Impact factor: 79.321

2.  Can the NICE "end-of-life premium" be given a coherent ethical justification?

Authors:  Richard Cookson
Journal:  J Health Polit Policy Law       Date:  2013-08-23       Impact factor: 2.265

3.  Unintended consequences of expensive cancer therapeutics—the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.

Authors:  Tito Fojo; Sham Mailankody; Andrew Lo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-12       Impact factor: 6.223

4.  Some inconsistencies in NICE's consideration of social values.

Authors:  Mike Paulden; James F O'Mahony; Anthony J Culyer; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2014-11       Impact factor: 4.981

5.  Which way now for the Cancer Drugs Fund?

Authors:  Andrew Jack
Journal:  BMJ       Date:  2014-09-09

6.  Clinical development success rates for investigational drugs.

Authors:  Michael Hay; David W Thomas; John L Craighead; Celia Economides; Jesse Rosenthal
Journal:  Nat Biotechnol       Date:  2014-01       Impact factor: 54.908

7.  Valuing health at the end of life: a stated preference discrete choice experiment.

Authors:  Koonal K Shah; Aki Tsuchiya; Allan J Wailoo
Journal:  Soc Sci Med       Date:  2014-11-13       Impact factor: 4.634

8.  Valuing QALYs at the end of life.

Authors:  Jose-Luis Pinto-Prades; Fernando-Ignacio Sánchez-Martínez; Belen Corbacho; Rachel Baker
Journal:  Soc Sci Med       Date:  2014-05-02       Impact factor: 4.634

9.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.

Authors:  Karl Claxton; Steve Martin; Marta Soares; Nigel Rice; Eldon Spackman; Sebastian Hinde; Nancy Devlin; Peter C Smith; Mark Sculpher
Journal:  Health Technol Assess       Date:  2015-02       Impact factor: 4.014

10.  Expected value of sample information calculations in medical decision modeling.

Authors:  A E Ades; G Lu; K Claxton
Journal:  Med Decis Making       Date:  2004 Mar-Apr       Impact factor: 2.583
View more
  4 in total

1.  The Cancer Drugs Fund in Practice and Under the New Framework.

Authors:  Celia Sabry-Grant; Kinga Malottki; Alexander Diamantopoulos
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Authors:  Jaclyn Beca; Don Husereau; Kelvin K W Chan; Neil Hawkins; Jeffrey S Hoch
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981

3.  Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.

Authors:  Rachel Baker; Helen Mason; Neil McHugh; Cam Donaldson
Journal:  Soc Sci Med       Date:  2021-04-02       Impact factor: 4.634

4.  EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.

Authors:  Rumona Dickson; Angela Boland; Rui Duarte; Eleanor Kotas; Nerys Woolacott; Robert Hodgson; Rob Riemsma; Sabine Grimm; Bram Ramaekers; Manuela Joore; Nasuh Büyükkaramikli; Eva Kaltenthaler; Matt Stevenson; Abdullah Pandor; Steve Edwards; Martin Hoyle; Jonathan Shepherd; Xavier Armoiry; Miriam Brazzelli
Journal:  Appl Health Econ Health Policy       Date:  2018-08       Impact factor: 2.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.